Dermata Therapeutics (DRMAW) Competitors $0.01 0.00 (-19.70%) Closing price 09:29 AM EasternExtended Trading$0.01 0.00 (0.00%) As of 09:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock DRMAW vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ACABW, BFRIW, BTMDW, BCTXW, and CALAShould you be buying Dermata Therapeutics stock or one of its competitors? The main competitors of Dermata Therapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), and Calithera Biosciences (CALA). These companies are all part of the "pharmaceutical products" industry. Dermata Therapeutics vs. 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Calithera Biosciences Dermata Therapeutics (NASDAQ:DRMAW) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, community ranking, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership. Does the MarketBeat Community prefer DRMAW or ATNFW? Dermata Therapeutics and 180 Life Sciences both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformDermata TherapeuticsN/AN/A180 Life SciencesN/AN/A Is DRMAW or ATNFW more profitable? Company Net Margins Return on Equity Return on Assets Dermata TherapeuticsN/A N/A N/A 180 Life Sciences N/A N/A N/A Does the media prefer DRMAW or ATNFW? In the previous week, 180 Life Sciences' average media sentiment score of 0.59 beat Dermata Therapeutics' score of 0.00 indicating that 180 Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment Dermata Therapeutics Neutral 180 Life Sciences Positive Which has better earnings and valuation, DRMAW or ATNFW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDermata TherapeuticsN/AN/AN/AN/AN/A180 Life SciencesN/AN/AN/AN/AN/A Summary180 Life Sciences beats Dermata Therapeutics on 1 of the 1 factors compared between the two stocks. Get Dermata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DRMAW and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRMAW vs. The Competition Export to ExcelMetricDermata TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$122.90M$5.44B$7.89BDividend YieldN/A3.69%5.37%4.22%P/E RatioN/A3.2924.8818.78Price / SalesN/A4,153.67388.51105.13Price / CashN/A13.0238.1834.62Price / BookN/A34.016.704.25Net IncomeN/A-$90.45M$3.22B$247.93M7 Day PerformanceN/A-0.70%-2.24%0.16%1 Month PerformanceN/A8.41%8.62%11.18%1 Year PerformanceN/A93.03%14.77%2.53% Dermata Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRMAWDermata TherapeuticsN/A$0.01-19.7%N/AN/A$0.00N/A0.008Gap UpATNFW180 Life SciencesN/A$0.01+3.8%N/A+0.0%$0.00N/A0.007Positive NewsGap UpLBPSW4D pharmaN/AN/AN/AN/A$0.00$522,000.000.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.01flatN/A-93.7%$0.00N/A0.002AIMDWAinosN/A$0.23-12.1%N/A+134.2%$0.00$20,729.000.0040Gap DownALVOWAlvotechN/A$1.29-2.3%N/AN/A$0.00$489.68M0.004Gap UpACABWAtlantic Coastal Acquisition Corp. IIN/A$0.02flatN/AN/A$0.00N/A0.0015BFRIWBiofronteraN/A$0.04+22.7%N/A-33.3%$0.00$37.32M0.0070Gap UpBTMDWbioteN/A$0.01+5.7%N/A-89.3%$0.00$197.19M0.00N/ABCTXWBriaCell TherapeuticsN/A$0.09-20.8%N/A-90.7%$0.00N/A0.008Gap DownCALACalithera BiosciencesN/A$0.00-98.0%N/A-99.5%$0.00N/A0.0060Gap Down Related Companies and Tools Related Companies ATNFW Competitors LBPSW Competitors AEHAW Competitors AIMDW Competitors ALVOW Competitors ACABW Competitors BFRIW Competitors BTMDW Competitors BCTXW Competitors CALA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRMAW) was last updated on 5/8/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredYour Wealth is Being Erased – Save It Before It’s Gone ForeverWhat If America's Gold Reserves Are a Lie? For decades, the U.S. government has claimed to have thousands o...Hamilton Gold Group | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Seeing how the media and other analysts are covering Trump’s actions – it’s laughable. At least it would be la...Porter & Company | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dermata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DRMAW Stock Free DRMAW Stock Alerts